Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myeloid, Acute 7Myelodysplastic Syndromes 2Leukemia 2Sarcoma, Myeloid 1Recurrence 1Myeloproliferative Disorders 1Leukemia, Myelomonocytic, Chronic 1Hematologic Neoplasms 1

Interventions

fludarabine 27Azacitidine 26venetoclax 23Cyclophosphamide 22Specimen Handling 21fludarabine phosphate 17Biopsy 16Whole-Body Irradiation 15Mycophenolic Acid 15Busulfan 15Melphalan 14Cytarabine 14Tacrolimus 13Granulocyte Colony-Stimulating Factor 12Decitabine 11Stem Cell Transplantation 10Injections 10Cyclosporine 10decitabine and cedazuridine drug combination 9Sirolimus 9Filgrastim 9Peripheral Blood Stem Cell Transplantation 8Thiotepa 7X-Rays 6Idarubicin 6ruxolitinib 5Cyclosporins 5Cladribine 5Methotrexate 4Magnetic Resonance Spectroscopy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × quizartinib × 90 days × Clear all
NCT04128748 2026-06-02

Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
52 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04493138 2026-05-04

Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
30 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡